Realcan Pharmaceutical Group Co., Ltd.

Total Valuation

Realcan Pharmaceutical Group Co., Ltd. carries a market capitalization of 3.03B, placing it among publicly traded companies globally. Its enterprise value stands at 6.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Realcan Pharmaceutical Group Co., Ltd. currently has 1.50B shares outstanding.

Valuation Ratios

Realcan Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 787.43. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at 2.53.

Enterprise Valuation

On an enterprise value basis, Realcan Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 164.48 and an EV/FCF ratio of 35.02. The EV/Sales ratio of 0.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 164.48 provides insight into valuation relative to core operating earnings.

Financial Position

Realcan Pharmaceutical Group Co., Ltd. maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 138.68, indicating elevated leverage, while an interest coverage ratio of -0.23 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Realcan Pharmaceutical Group Co., Ltd. has paid -45.07M in income taxes, reflecting an effective tax rate of 19.16.

Stock Price Statistics

Realcan Pharmaceutical Group Co., Ltd.'s stock has declined approximately -10.43771% over the past 52 weeks. The 50-day moving average sits at 2.88, while the 200-day moving average is 3.15.

Income Statement

Over the trailing twelve months, Realcan Pharmaceutical Group Co., Ltd. generated 7.48B in revenue and converted that into 5.68M in net income, yielding earnings per share of 0.02. EBITDA reached -47.58M, while operating income came in at -47.58M.

Balance Sheet

Realcan Pharmaceutical Group Co., Ltd. holds 5.98B in cash and equivalents against 7.72B in total debt, resulting in a net debt position of 1.67B. Total book value stands at 1.76B, with working capital of 1.08B providing operational flexibility.

Cash Flow

After subtracting -165.52M in capital expenditures, free cash flow totaled -165.52M - equivalent to -0.11 per share.

Margins

Realcan Pharmaceutical Group Co., Ltd. operates with a gross margin of 9.99, reflecting its pricing power and cost economics. The operating margin of -0.64 and net profit margin of 0.08 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 411.70 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Realcan Pharmaceutical Group Co., Ltd.'s most recent stock split took place on May 15, 2017 with a 10:23 split ratio.

Scores

Realcan Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 0.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.